IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
IMPemBra:一项 2 期研究,比较帕博利珠单抗与间歇性/短期双重 MAPK 通路抑制联合帕博利珠单抗治疗携带 BRAFV600 突变的黑色素瘤患者的效果
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.3
doi:10.1136/jitc-2023-006821
Elisa A Rozeman, Judith M Versluis, Karolina Sikorska, Esmée P Hoefsmit, Petros Dimitriadis, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Aysegul Sari, Stijn W T P J Heijmink, Daan van den Broek, Annegien Broeks, Jan W